Combination of oxaliplatin and capecitabine (CAPOX) in first and second-line treatment for metastatic colorectal carcinoma (MCRC).

被引：0
|
作者：
Lopez-Vivanco, G [1 ]
Muñoz, A [1 ]
Mañe, JM [1 ]
Ferreiro, J [1 ]
Rubio, I [1 ]
Fuente, N [1 ]
Perez-Hoyos, T [1 ]
Lopez-Argumedo, G [1 ]
Viteri, A [1 ]
Barcelo-Galindez, R [1 ]
机构：
[1] Hosp Cruces, Bilbao, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3701
引用
收藏
页码：294S / 294S
页数：1
相关论文
共 50 条
  • [31] Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer
    Bazarbashi, Shouki
    Aljubran, Ali
    Alzahrani, Ahmad
    Mohieldin, Ahmed
    Soudy, Hussein
    Shoukri, Mohammed
    [J]. CANCER MEDICINE, 2015, 4 (10): : 1505 - 1513
  • [32] A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
    E Vasile
    G Masi
    L Fornaro
    S Cupini
    F Loupakis
    S Bursi
    I Petrini
    S Di Donato
    I M Brunetti
    S Ricci
    A Antonuzzo
    S Chiara
    D Amoroso
    M Andreuccetti
    A Falcone
    [J]. British Journal of Cancer, 2009, 100 : 1720 - 1724
  • [33] Phase II trial of second-line chemotherapy in metastatic pancreas cancer with the combination of oxaliplatin (Ox) and capecitabine (Cp)
    Blesa, J. Gasent
    Candel, V. Alberola
    Marco, V. Giner
    Juan, O.
    Pulla, M. Provencio
    Llorca, C.
    Gravalos, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Metastatic colorectal cancer:: First- and second-line treatment in 2005
    Rougier, P
    Lepère, C
    [J]. SEMINARS IN ONCOLOGY, 2005, 32 (06) : S15 - S20
  • [35] Capecitabine single agent or in combination in the routine first-line treatment of a predominantly elderly population with metastatic colorectal cancer (MCRC)
    Schroeder, J.
    Goehler, T.
    Grothe, W.
    Tschechne, B.
    Valdix, A. R.
    Harich, H. D.
    Kluensch, F.
    Hofheinz, R. D.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 337 - 337
  • [36] Treatment patterns and costs in second-line (2L) metastatic colorectal cancer (mCRC)
    Teitelbaum, April H.
    Evans, Dana
    Yu, Elaine
    Morlock, Robert
    Byfield, Stacey DaCosta
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [37] Combination chemotherapy with oxaliplatin and capecitabine as second line treatment of metastatic colorectal cancer. The Debrecen University Medical Center experience
    Andras, CA
    Szanto, JS
    [J]. ANNALS OF ONCOLOGY, 2006, 17
  • [38] Capecitabine plus oxaliplatin (XELOX) vs. 5-FU/LV + oxaliplatin (FOLFOX4) as second-line treatment for patients with metastatic colorectal cancer (MCRC): Phase III trial results
    Rothenberg, M.
    Navarro, M.
    Butts, C.
    Bang, Y.
    Cox, J.
    Goel, R.
    Gollins, S.
    Siu, L.
    Cunningham, D.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 238 - 239
  • [39] Sequential capecitabine-based treatment of patients with metastatic colorectal cancer (MCRC) combined with oxaliplatin first-line: A retrospective analysis.
    Hoeffkes, HG
    Arland, M
    Freidank, A
    Ranze, O
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 277S - 277S
  • [40] Capecitabine/oxaliplatin as first-line treatment for metastatic colorectal cancer: a meta-analysis
    Zhao, G.
    Gao, P.
    Yang, K. H.
    Tian, J. H.
    Ma, B.
    [J]. COLORECTAL DISEASE, 2010, 12 (07) : 615 - 623
12345